Trial Profile

Phase III study evaluating the efficacy and safety of epinephrine administration with ARS-1 in food allergy patients

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 04 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

19 Sep 2025 According to an ARS Pharmaceuticals media release, the Pharmaceuticals and Medical Devices Agency (PMDA), the Japanese authority responsible for the scientific review of drugs and medical devices, has granted approval for neffy (epinephrine nasal spray) 1 mg and 2 mg doses, for the emergency treatment of allergic reactions (anaphylaxis) in adults and children who weigh greater than 15 kilograms.
26 Feb 2024 Results assessing safety and efficacy of neffy, epinephrine nasal spray presented at the 2024 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
09 Feb 2024 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com